-+ 0.00%
-+ 0.00%
-+ 0.00%

Conexeu net loss widens to USD 2.3 million in Q2 FY26; revenue flat with no revenue

PUBT·06/15/2026 20:31:56
Listen to the news
Conexeu net loss widens to USD 2.3 million in Q2 FY26; revenue flat with no revenue
  • Conexeu Sciences posted a net loss of USD 2.3 million for the three months ended April 30, 2026, widening from USD 458,050.
  • Operating loss widened to USD 2.38 million from USD 456,981, while other income swung to USD 76,085 from an expense of USD 1,069.
  • Revenue was unchanged at no revenue, as consulting expense climbed to USD 1.23 million from USD 149,586.
  • Cash and cash equivalents totaled about USD 6.8 million at April 30, 2026; the company estimated cash runway of about 9 to 11 months.
  • Shares began trading on Nasdaq on May 21, 2026 under the symbol CNXU; a planned FDA 510(k) submission remains a key near-term focus.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conexeu Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-26-003207), on June 15, 2026, and is solely responsible for the information contained therein.